Ayurvedic medicine to reduce HbA1c is a topic of growing interest, particularly among South Asian communities in the UK where traditional herbal remedies have long been used alongside conventional care. HbA1c — glycated haemoglobin — is the key blood test used to monitor long-term blood glucose control in diabetes, and keeping it within a safe range is essential to reducing the risk of serious complications. This article examines the Ayurvedic herbs most commonly used for blood sugar management, reviews the current clinical evidence, outlines important safety considerations under MHRA guidance, and explains the proven NHS-recommended strategies that should form the foundation of any diabetes management plan.

What Is HbA1c and Why Does It Matter for Diabetes Management?

HbA1c reflects average blood glucose over two to three months and is the primary marker of glycaemic control in UK diabetes care; NICE targets 48 mmol/mol for lifestyle-managed type 2 diabetes and 53 mmol/mol where hypoglycaemia risk exists.

HbA1c — glycated haemoglobin — is a blood test that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds to haemoglobin inside red blood cells; the higher the blood sugar, the greater the proportion of glycated haemoglobin. Results are expressed in millimoles per mole (mmol/mol) in the UK, following standardisation by the International Federation of Clinical Chemistry (IFCC).

For people living with type 2 diabetes, NICE guidelines (NG28) recommend an HbA1c target of 48 mmol/mol (6.5%) for those managed by lifestyle alone or by a medicine that does not carry a risk of hypoglycaemia. A target of 53 mmol/mol (7.0%) is generally recommended for those taking a medicine that can cause hypoglycaemia, such as a sulphonylurea (e.g., gliclazide) or insulin. These targets should always be individualised through shared decision-making, taking into account factors such as frailty, significant comorbidities, risk of hypoglycaemia, and patient preference — as set out in NICE NG28.

It is also worth noting that HbA1c can be unreliable in certain circumstances, including in people with anaemia, haemoglobinopathies (such as sickle cell disease or thalassaemia), chronic kidney disease, or during pregnancy. In these situations, your care team may use alternative measures of glycaemic control, such as fructosamine or continuous glucose monitoring (CGM).

Persistently elevated HbA1c is associated with an increased risk of serious long-term complications, including:

• Diabetic retinopathy (damage to the retina)

• Peripheral neuropathy (nerve damage, particularly in the feet)

• Nephropathy (kidney disease)

• Cardiovascular disease, including heart attack and stroke

NICE recommends measuring HbA1c every three to six months until levels are stable on a consistent treatment regimen, then every six months thereafter. Because it captures a longer-term picture than a single fasting glucose reading, it is considered one of the most reliable markers of glycaemic control available in routine NHS practice.

Ayurvedic Remedies Commonly Used to Support Blood Sugar Control

Bitter melon, fenugreek, Gymnema sylvestre, turmeric, and neem are the most commonly used Ayurvedic remedies for blood sugar, but no herbal product is licensed in the UK to treat diabetes and product quality varies considerably.

Ayurveda is a traditional system of medicine originating in the Indian subcontinent, with a history spanning thousands of years. It employs a combination of herbal preparations, dietary modifications, yoga, and lifestyle practices to restore balance within the body. Several Ayurvedic herbs and formulations are widely used — particularly within South Asian communities in the UK — with the intention of supporting blood glucose regulation.

The most frequently cited remedies in the context of blood sugar management include:

• Bitter melon (Momordica charantia): Believed in traditional practice to have insulin-like activity; proposed mechanisms are based largely on preclinical (laboratory and animal) studies and have not been reliably established in humans.

• Fenugreek (Trigonella foenum-graecum): Rich in soluble fibre; thought to slow carbohydrate absorption and improve insulin sensitivity, though human evidence remains limited.

• Gymnema sylvestre (Gurmar): Traditionally used to reduce sugar cravings; some preclinical studies have suggested possible effects on pancreatic function, but these findings have not been confirmed in robust human trials.

• Turmeric (Curcuma longa): Contains curcumin, which has demonstrated anti-inflammatory properties in laboratory studies; clinical relevance in humans is uncertain.

• Neem (Azadirachta indica): Used in Ayurvedic practice for its purported hypoglycaemic effects, based primarily on traditional use and animal studies.

• Triphala: A compound formulation of three fruits, sometimes used to support digestive health and metabolic function.

These remedies are available in the UK in various forms — capsules, powders, teas, and tinctures — and are sold in health food shops and online. No herbal product is licensed in the UK to treat diabetes, and products registered under the Traditional Herbal Registration (THR) scheme cannot make claims to treat serious medical conditions. Product quality, purity, and dosage can vary considerably between manufacturers.

Caution is particularly advised for people who are pregnant or breastfeeding, and for those with significant liver or kidney disease, who should not use these products without explicit guidance from a clinician. Their use should always be considered alongside — not instead of — conventional medical care, and you should never stop or alter your prescribed diabetes medicines without first speaking to your GP or diabetes nurse.

What Does the Clinical Evidence Say About These Treatments?

Evidence for Ayurvedic medicines reducing HbA1c is low-certainty; no Ayurvedic remedy has MHRA or EMA approval for diabetes, and NICE does not recommend replacing metformin, SGLT-2 inhibitors, or GLP-1 agonists with herbal preparations.

The scientific evidence base for Ayurvedic medicines in reducing HbA1c remains limited, inconsistent, and largely preliminary. While a number of small-scale clinical trials and systematic reviews have explored individual herbs, most studies are characterised by small sample sizes, short durations, variable product quality, and methodological weaknesses that make it difficult to draw firm conclusions. Any positive findings should be interpreted as low-certainty evidence.

Some systematic reviews have found that bitter melon showed modest reductions in fasting blood glucose in certain trials, but results for HbA1c specifically were inconclusive. Similarly, fenugreek has demonstrated some benefit in reducing postprandial glucose in short-term studies, likely due to its high soluble fibre content slowing gastric emptying; however, robust, long-term randomised controlled trials (RCTs) demonstrating clinically meaningful HbA1c reductions are lacking.

Gymnema sylvestre has attracted interest, and some small studies suggest it may modestly affect glycaemic markers when used alongside conventional treatment. However, claims regarding regeneration of pancreatic beta cells are based on preclinical data and have not been demonstrated in humans; these findings should not be taken as established fact. Curcumin (from turmeric) has shown anti-inflammatory effects in laboratory and animal models, but bioavailability in humans is poor without specific formulations, and clinical evidence for HbA1c reduction remains weak.

Importantly, NICE does not recommend herbal or Ayurvedic medicines for lowering HbA1c in type 2 diabetes, and no Ayurvedic medicine has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) as a treatment for diabetes or for lowering HbA1c. The evidence does not currently support replacing NICE-recommended pharmacological therapies — such as metformin, SGLT-2 inhibitors, or GLP-1 receptor agonists — with Ayurvedic preparations. Any apparent benefit observed in studies may also reflect concurrent lifestyle changes rather than the herbal remedy itself.

Safety Concerns and MHRA Guidance on Herbal Medicines in the UK

Key safety risks include heavy metal contamination, additive hypoglycaemia with insulin or sulphonylureas, and hepatotoxicity; only THR-registered products verified on the MHRA public register have been assessed for quality and safety.

Safety is a critical consideration when evaluating Ayurvedic medicines, and patients should be aware that 'natural' does not automatically mean 'safe'. The MHRA regulates herbal medicines in the UK under the Traditional Herbal Registration (THR) scheme, which requires products to meet standards of quality and safety — but does not require proof of clinical efficacy. Many Ayurvedic products sold online or in shops fall outside this scheme entirely, meaning their quality, purity, and dosage cannot be guaranteed.

When purchasing herbal products, look for the THR logo and registration number on the packaging, and verify the product on the MHRA's public register of licensed herbal medicines (available at gov.uk/check-if-a-medicine-is-licensed). If a product does not carry a THR number, it has not been assessed for quality or safety by the MHRA.

Several specific safety concerns have been documented:

• Heavy metal contamination: Some traditional Ayurvedic preparations intentionally contain metals such as lead, mercury, or arsenic (known as rasa shastra formulations). The MHRA has issued warnings about products found to contain toxic levels of heavy metals, which can cause serious organ damage.

• Drug interactions: Herbs such as bitter melon and fenugreek may have additive hypoglycaemic effects when combined with insulin or sulphonylureas (e.g., gliclazide), potentially causing dangerous hypoglycaemia. Some herbal products may also interact with anticoagulants (e.g., warfarin) and other medicines with a narrow therapeutic index. Your pharmacist can check for interactions using the BNF.

• Hepatotoxicity: Certain Ayurvedic herbs have been associated with liver toxicity in case reports.

• Unlicensed products: Many products are imported and may not comply with UK safety standards.

• Vulnerable groups: People who are pregnant, breastfeeding, or have significant liver or kidney disease should avoid these products unless a clinician has specifically advised otherwise.

Patients should seek prompt medical advice if they experience symptoms such as unexplained fatigue, jaundice, episodes of low blood sugar, or any new symptoms after starting a herbal remedy. The MHRA Yellow Card scheme allows both patients and healthcare professionals to report suspected adverse reactions to herbal medicines at yellowcard.mhra.gov.uk — its use is strongly encouraged. Always purchase THR-registered products where possible and verify them on the MHRA's public register before use.

How to Discuss Ayurvedic Approaches With Your NHS Care Team

Disclose all herbal remedy use to your GP, diabetes nurse, or pharmacist, providing exact product names and doses so interactions can be checked and use recorded on your Summary Care Record.

Open and honest communication with your NHS diabetes care team is essential if you are considering or already using Ayurvedic remedies. Research consistently shows that a significant proportion of patients do not disclose complementary medicine use to their doctors, often due to concerns about being judged or dismissed. However, non-disclosure carries real clinical risks, particularly around drug interactions and monitoring.

Worried about interactions with other medications? Speak to one of our pharmacists →

When speaking with your GP, diabetes nurse, or pharmacist, consider the following approach:

• Be specific: Bring the product with you or note down the exact name, ingredients, dose, and frequency of use.

• Ask for it to be recorded: Request that all herbal products are added to your medication list and Summary Care Record, so that any clinician treating you is aware of what you are taking.

• Ask about interactions: Your pharmacist can check for potential interactions with your prescribed diabetes medications and other medicines.

• Request monitoring: If you choose to use an Ayurvedic remedy alongside conventional treatment, ask for more frequent HbA1c or blood glucose monitoring to detect any unexpected changes — in either direction.

• Discuss your motivations: Whether driven by cultural practice, dissatisfaction with side effects, or a desire for a more holistic approach, sharing your reasons helps your care team tailor advice appropriately.

NICE guidance on shared decision-making (NG197) and patient experience in adult NHS services (CG138) supports a person-centred, culturally sensitive approach to diabetes management. South Asian patients — who are at significantly higher risk of type 2 diabetes — may have deeply held beliefs about traditional medicine, and a collaborative, non-judgemental conversation is far more productive than avoidance. Your care team can help you weigh the available evidence, identify safer options, and ensure that any complementary approach does not compromise your overall diabetes management plan. Never stop or reduce your prescribed diabetes medicines without first discussing this with your GP or diabetes nurse.

Proven NHS-Recommended Ways to Lower HbA1c Safely

NICE-recommended approaches — including dietary modification, physical activity, weight loss support via the NHS Low Calorie Diet Programme, and pharmacological therapies such as metformin and SGLT-2 inhibitors — have robust evidence for safely reducing HbA1c.

While interest in Ayurvedic approaches is understandable, there are well-evidenced, NICE-approved strategies that have been shown to produce clinically meaningful reductions in HbA1c. These should form the foundation of any diabetes management plan.

Lifestyle interventions remain among the most powerful tools available, particularly in the earlier stages of type 2 diabetes:

• Dietary modification: A low-calorie, low-glycaemic-index, or Mediterranean-style diet can lead to meaningful improvements in HbA1c. Referral to a registered dietitian is available through your GP, and structured dietary advice is a core component of diabetes care under NICE NG28.

• Physical activity: The UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, combined with muscle-strengthening activities on two or more days per week. Regular physical activity improves insulin sensitivity and contributes to better glycaemic control.

• Weight loss: Even a modest reduction in body weight can significantly improve glycaemic control. The NHS Low Calorie Diet Programme offers structured support for eligible adults with type 2 diabetes (typically those with a BMI of 27–45 kg/m² and diagnosed within the last six years); speak to your GP about whether you qualify. Evidence from the UK-based DiRECT trial has demonstrated that substantial weight loss achieved through a low-calorie diet can lead to remission of type 2 diabetes in some people, particularly those diagnosed more recently.

Pharmacological therapies recommended by NICE (NG28) include:

• Metformin — first-line therapy for most people, well-tolerated, with a strong safety record

• SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) — offer additional cardiovascular and renal benefits in appropriate patients

• GLP-1 receptor agonists (e.g., semaglutide) — effective for both HbA1c reduction and weight management

The choice of medicine is individualised according to NICE NG28, taking into account cardiovascular and renal risk, BMI, risk of hypoglycaemia, and patient preference.

Structured diabetes education programmes such as DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed — for type 2 diabetes) and DAFNE (Dose Adjustment For Normal Eating — for type 1 diabetes) are available on the NHS and have been shown to improve self-management skills and glycaemic outcomes. Ask your GP or diabetes nurse for a referral.

If your HbA1c remains above your agreed target despite current treatment, speak to your GP or diabetes nurse — there are many safe, evidence-based options available to help you achieve better control.

Frequently Asked Questions